Design of MGTA-117, an Antibody-Drug Conjugate for Stem Cell Conditioning & Transplantation in Malignant Disease & Gene Therapy

Time: 9:40 am
day: Day One


  • Stem cell transplantation is a potentially curative therapy for life-threatening diseases, yet its use is limited by the need for “conditioning” recipients with intensive chemotherapy or radiation
  • Hear about MGTA-117, an antibody-drug conjugate intended to condition patients by delivering an amanitin payload to CD117-expressing stem cells, while limiting systemic exposure
  • Understand how MGTA-117 incorporates a number of design innovations to maximize effectiveness for transplant conditioning which have been validated by preclinical testing, and clinical data is expected in 2022